Yi Guo 1 , Shiyun Luo 1 , Yongxin Ye 1 , Songping Yin 1 , Jiahua Fan 1 , Min Xia 1 Show Affiliations »
Abstract
Show RCT »
Hide RCT «
CONTEXT: Intermittent fasting (IF) is an effective strategy to improve cardiometabolic health. OBJECTIVE: The objective of this work is to examine the effects of IF on cardiometabolic risk factors and the gut microbiota in patients with metabolic syndrome (MS ). DESIGN AND SETTING: A randomized clinical trial was conducted at a community health service center . PATIENTS: Participants included adults with MS, age 30 to 50 years . INTERVENTION: Intervention consisted of 8 weeks of "2-day" modified IF. MAIN OUTCOME MEASURE: Cardiometabolic risk factors including body composition, oxidative stress, inflammatory cytokines, and endothelial function were assessed at baseline and at 8 weeks. The diversity, composition, and functional pathways of the gut microbiota, as well as circulating gut-derived metabolites, were measured. RESULTS: Thirty-nine patients with MS were included: 21 in the IF group and 18 in the control group . On fasting days, participants in the IF group reduced 69% of their calorie intake compared to nonfasting days. The 8-week IF significantly reduced fat mass, ameliorated oxidative stress, modulated inflammatory cytokines, and improved vasodilatory parameters . Furthermore, IF induced significant changes in gut microbiota communities , increased the production of short-chain fatty acids , and decreased the circulating levels of lipopolysaccharides . The gut microbiota alteration attributed to the IF was significantly associated with cardiovascular risk factors and resulted in distinct genetic shifts of carbohydrate metabolism in the gut community. CONCLUSION: IF induces a significant alteration of the gut microbial community and functional pathways in a manner closely associated with the mitigation of cardiometabolic risk factors . The study provides potential mechanistic insights into the prevention of adverse outcomes associated with MS. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
RCT Entities: Population
Interventions
Outcomes
CONTEXT: Intermittent fasting (IF) is an effective strategy to improve cardiometabolic health. OBJECTIVE: The objective of this work is to examine the effects of IF on cardiometabolic risk factors and the gut microbiota in patients with metabolic syndrome (MS). DESIGN AND SETTING: A randomized clinical trial was conducted at a community health service center. PATIENTS : Participants included adults with MS, age 30 to 50 years. INTERVENTION: Intervention consisted of 8 weeks of "2-day" modified IF. MAIN OUTCOME MEASURE: Cardiometabolic risk factors including body composition, oxidative stress, inflammatory cytokines, and endothelial function were assessed at baseline and at 8 weeks. The diversity, composition, and functional pathways of the gut microbiota, as well as circulating gut-derived metabolites, were measured. RESULTS: Thirty-nine patients with MS were included: 21 in the IF group and 18 in the control group. On fasting days, participants in the IF group reduced 69% of their calorie intake compared to nonfasting days. The 8-week IF significantly reduced fat mass, ameliorated oxidative stress, modulated inflammatory cytokines, and improved vasodilatory parameters. Furthermore, IF induced significant changes in gut microbiota communities, increased the production of short-chain fatty acids , and decreased the circulating levels of lipopolysaccharides . The gut microbiota alteration attributed to the IF was significantly associated with cardiovascular risk factors and resulted in distinct genetic shifts of carbohydrate metabolism in the gut community. CONCLUSION: IF induces a significant alteration of the gut microbial community and functional pathways in a manner closely associated with the mitigation of cardiometabolic risk factors. The study provides potential mechanistic insights into the prevention of adverse outcomes associated with MS. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Entities: Chemical
Disease
Species
Keywords:
cardiometabolic risk factors; gut microbiota; intermittent fasting; metabolic syndrome
Year: 2021
PMID： 33017844 DOI： 10.1210/clinem/dgaa644
Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN： 0021-972X Impact factor: 5.958